This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024. 

Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rounds marking the start of the year, they examine the factors behind this ongoing challenge while also highlighting positive industry developments.

To learn more about the topics in this episode: 
No reprieve for biopharma layoffs in Q1: Fierce Biotech analysis
Fierce Biotech Layoff Tracker 2024

This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024. 
Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rounds marking the start of the year, they examine the factors behind this ongoing challenge while also highlighting positive industry developments.
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/biopharma-layoffs-dont-see-reprieve-q1-2024-fierce-biotech-analysis">No reprieve for biopharma layoffs in Q1: Fierce Biotech analysis</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024">Fierce Biotech Layoff Tracker 2024</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement